Do analysts recommend SIGA or TCRX?

TScan Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 538.98%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TScan Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media prefer TCRX or SGMT?

In the previous week, TScan Therapeutics had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 3 mentions for TScan Therapeutics and 1 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 1.72 beat TScan Therapeutics' score of 0.45 indicating that Sagimet Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TScan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sagimet Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer ARTV or TCRX?

In the previous week, Artiva Biotherapeutics had 3 more articles in the media than TScan Therapeutics. MarketBeat recorded 6 mentions for Artiva Biotherapeutics and 3 mentions for TScan Therapeutics. Artiva Biotherapeutics' average media sentiment score of 1.61 beat TScan Therapeutics' score of 0.45 indicating that Artiva Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive TScan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

TScan Therapeutics (TCRX) Competitors

$0.94 +0.01 (+1.56%)

As of 12:03 PM Eastern

Compare

TCRX vs. SIGA, SGMT, ACIU, FULC, and ARTV

Should you buy TScan Therapeutics stock or one of its competitors? MarketBeat compares TScan Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TScan Therapeutics include Siga Technologies (SIGA), Sagimet Biosciences (SGMT), AC Immune (ACIU), Fulcrum Therapeutics (FULC), and Artiva Biotherapeutics (ARTV). These companies are all part of the "pharmaceutical products" industry.

How does TScan Therapeutics compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

Siga Technologies has a net margin of 21.58% compared to TScan Therapeutics' net margin of -1,360.61%. Siga Technologies' return on equity of 10.60% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	21.58%	10.60%	8.94%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

Siga Technologies has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

TScan Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 538.98%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, TScan Therapeutics had 3 more articles in the media than Siga Technologies. MarketBeat recorded 3 mentions for TScan Therapeutics and 0 mentions for Siga Technologies. TScan Therapeutics' average media sentiment score of 0.45 beat Siga Technologies' score of 0.00 indicating that TScan Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Siga Technologies	Neutral
TScan Therapeutics	Neutral

55.4% of Siga Technologies shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 2.7% of Siga Technologies shares are owned by insiders. Comparatively, 6.3% of TScan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Siga Technologies has higher revenue and earnings than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	2.65	$23.28M	$0.27	12.94
TScan Therapeutics	$10.32M	5.95	-$129.77M	-$0.96	N/A

Summary

TScan Therapeutics beats Siga Technologies on 9 of the 16 factors compared between the two stocks.

How does TScan Therapeutics compare to Sagimet Biosciences?

TScan Therapeutics (NASDAQ:TCRX) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Sagimet Biosciences has lower revenue, but higher earnings than TScan Therapeutics. Sagimet Biosciences is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	5.95	-$129.77M	-$0.96	N/A
Sagimet Biosciences	$2M	114.68	-$51.04M	-$1.34	N/A

In the previous week, TScan Therapeutics had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 3 mentions for TScan Therapeutics and 1 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 1.72 beat TScan Therapeutics' score of 0.45 indicating that Sagimet Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TScan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sagimet Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

TScan Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.35, indicating that its share price is 235% more volatile than the broader market.

TScan Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 538.98%. Sagimet Biosciences has a consensus target price of $25.57, indicating a potential upside of 263.23%. Given TScan Therapeutics' higher possible upside, equities research analysts plainly believe TScan Therapeutics is more favorable than Sagimet Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 6.3% of TScan Therapeutics shares are owned by insiders. Comparatively, 11.5% of Sagimet Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Sagimet Biosciences has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. Sagimet Biosciences' return on equity of -37.57% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%
Sagimet Biosciences	N/A	-37.57%	-35.52%

Summary

Sagimet Biosciences beats TScan Therapeutics on 11 of the 16 factors compared between the two stocks.

How does TScan Therapeutics compare to AC Immune?

AC Immune (NASDAQ:ACIU) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

In the previous week, TScan Therapeutics had 3 more articles in the media than AC Immune. MarketBeat recorded 3 mentions for TScan Therapeutics and 0 mentions for AC Immune. TScan Therapeutics' average media sentiment score of 0.45 beat AC Immune's score of 0.00 indicating that TScan Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
AC Immune	Neutral
TScan Therapeutics	Neutral

AC Immune has higher earnings, but lower revenue than TScan Therapeutics. AC Immune is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	53.72	-$85.03M	-$0.82	N/A
TScan Therapeutics	$10.32M	5.95	-$129.77M	-$0.96	N/A

AC Immune currently has a consensus price target of $7.50, suggesting a potential upside of 229.67%. TScan Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 538.98%. Given TScan Therapeutics' higher possible upside, analysts plainly believe TScan Therapeutics is more favorable than AC Immune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 4.6% of AC Immune shares are owned by company insiders. Comparatively, 6.3% of TScan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

AC Immune has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

TScan Therapeutics has a net margin of -1,360.61% compared to AC Immune's net margin of -1,788.02%. TScan Therapeutics' return on equity of -91.94% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

Summary

TScan Therapeutics beats AC Immune on 9 of the 15 factors compared between the two stocks.

How does TScan Therapeutics compare to Fulcrum Therapeutics?

Fulcrum Therapeutics (NASDAQ:FULC) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Fulcrum Therapeutics has higher revenue and earnings than TScan Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$80M	3.10	-$74.88M	-$1.15	N/A
TScan Therapeutics	$10.32M	5.95	-$129.77M	-$0.96	N/A

Fulcrum Therapeutics presently has a consensus price target of $8.20, indicating a potential upside of 120.13%. TScan Therapeutics has a consensus price target of $6.00, indicating a potential upside of 538.98%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Fulcrum Therapeutics has a beta of 3.01, indicating that its stock price is 201% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market.

In the previous week, TScan Therapeutics had 3 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 3 mentions for TScan Therapeutics and 0 mentions for Fulcrum Therapeutics. TScan Therapeutics' average media sentiment score of 0.45 beat Fulcrum Therapeutics' score of 0.34 indicating that TScan Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Fulcrum Therapeutics	Neutral
TScan Therapeutics	Neutral

89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 7.3% of Fulcrum Therapeutics shares are held by insiders. Comparatively, 6.3% of TScan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Fulcrum Therapeutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. Fulcrum Therapeutics' return on equity of -27.80% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-27.80%	-26.32%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

Summary

Fulcrum Therapeutics and TScan Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does TScan Therapeutics compare to Artiva Biotherapeutics?

Artiva Biotherapeutics (NASDAQ:ARTV) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

82.8% of TScan Therapeutics shares are owned by institutional investors. 21.4% of Artiva Biotherapeutics shares are owned by insiders. Comparatively, 6.3% of TScan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Artiva Biotherapeutics had 3 more articles in the media than TScan Therapeutics. MarketBeat recorded 6 mentions for Artiva Biotherapeutics and 3 mentions for TScan Therapeutics. Artiva Biotherapeutics' average media sentiment score of 1.61 beat TScan Therapeutics' score of 0.45 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
TScan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Artiva Biotherapeutics has higher earnings, but lower revenue than TScan Therapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	962.99	-$83.86M	-$3.54	N/A
TScan Therapeutics	$10.32M	5.95	-$129.77M	-$0.96	N/A

Artiva Biotherapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

Artiva Biotherapeutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. Artiva Biotherapeutics' return on equity of -73.15% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-73.15%	-62.74%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

Artiva Biotherapeutics presently has a consensus price target of $39.00, indicating a potential upside of 300.45%. TScan Therapeutics has a consensus price target of $6.00, indicating a potential upside of 538.98%. Given TScan Therapeutics' higher probable upside, analysts clearly believe TScan Therapeutics is more favorable than Artiva Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Artiva Biotherapeutics beats TScan Therapeutics on 11 of the 17 factors compared between the two stocks.

Get TScan Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TCRX vs. The Competition

Export

Metric	TScan Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$61.36M	$3.64B	$6.80B	$12.42B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-0.98	20.63	27.05	24.17
Price / Sales	5.95	304.98	517.90	92.83
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	0.43	8.05	10.65	6.23
Net Income	-$129.77M	$23.81M	$3.59B	$331.42M
7 Day Performance	0.97%	-1.53%	-0.84%	-1.22%
1 Month Performance	2.07%	2.16%	1.42%	-1.36%
1 Year Performance	-48.69%	44.29%	24.75%	18.43%

TScan Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TCRX TScan Therapeutics	4.0787 of 5 stars	$0.94 +1.6%	$6.00 +539.0%	-49.2%	$61.36M	$10.32M	N/A	100	News Coverage
SIGA Siga Technologies	0.4151 of 5 stars	$3.51 -2.9%	N/A	-47.4%	$251.38M	$94.57M	12.98	40
SGMT Sagimet Biosciences	3.4867 of 5 stars	$7.68 +7.4%	$25.57 +233.0%	-23.9%	$250.21M	$2M	N/A	8
ACIU AC Immune	2.2174 of 5 stars	$2.45 -0.2%	$7.50 +206.7%	+8.7%	$248.83M	$4.31M	N/A	140
FULC Fulcrum Therapeutics	3.1897 of 5 stars	$3.62 +2.1%	$8.20 +126.8%	-52.7%	$240.87M	$80M	N/A	100	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TCRX) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TScan Therapeutics (TCRX) Competitors

TCRX vs. SIGA, SGMT, ACIU, FULC, and ARTV

How does TScan Therapeutics compare to Siga Technologies?

Summary

How does TScan Therapeutics compare to Sagimet Biosciences?

Summary

How does TScan Therapeutics compare to AC Immune?

Summary

How does TScan Therapeutics compare to Fulcrum Therapeutics?

Summary

How does TScan Therapeutics compare to Artiva Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX vs. The Competition

TScan Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TScan Therapeutics (TCRX) Competitors

TCRX vs. SIGA, SGMT, ACIU, FULC, and ARTV

How does TScan Therapeutics compare to Siga Technologies?

Is SIGA or TCRX more profitable?

Which has more volatility and risk, SIGA or TCRX?

Do analysts recommend SIGA or TCRX?

Does the media refer more to SIGA or TCRX?

Do institutionals & insiders have more ownership in SIGA or TCRX?

Which has better earnings & valuation, SIGA or TCRX?

Summary

How does TScan Therapeutics compare to Sagimet Biosciences?

Which has preferable earnings and valuation, TCRX or SGMT?

Does the media prefer TCRX or SGMT?

Which has more volatility and risk, TCRX or SGMT?

Do analysts rate TCRX or SGMT?

Do institutionals and insiders believe in TCRX or SGMT?

Is TCRX or SGMT more profitable?

Summary

How does TScan Therapeutics compare to AC Immune?

Does the media favor ACIU or TCRX?

Which has stronger valuation and earnings, ACIU or TCRX?

Do analysts recommend ACIU or TCRX?

Do institutionals and insiders hold more shares of ACIU or TCRX?

Which has more volatility and risk, ACIU or TCRX?

Is ACIU or TCRX more profitable?

Summary

How does TScan Therapeutics compare to Fulcrum Therapeutics?

Which has stronger earnings & valuation, FULC or TCRX?

Do analysts recommend FULC or TCRX?

Which has more risk & volatility, FULC or TCRX?

Does the media prefer FULC or TCRX?

Do institutionals & insiders have more ownership in FULC or TCRX?

Is FULC or TCRX more profitable?

Summary

How does TScan Therapeutics compare to Artiva Biotherapeutics?

Do insiders and institutionals believe in ARTV or TCRX?

Does the media prefer ARTV or TCRX?

Which has higher valuation and earnings, ARTV or TCRX?

Which has more risk and volatility, ARTV or TCRX?

Is ARTV or TCRX more profitable?

Do analysts prefer ARTV or TCRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX vs. The Competition

TScan Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools